GSD Type III (Forbes)

GSD type III is a rare inherited disorder caused by a deficiency of the debranching enzyme needed to fully break down glycogen, leading to abnormal glycogen build-up in the liver and, in most cases, muscle and heart. It typically presents in infancy with a large liver and low blood sugar. Unlike GSD I, muscle weakness and heart involvement are common additional features.

It is caused by inherited mutations in the AGL gene, which codes for the glycogen debranching enzyme, and follows an autosomal recessive pattern requiring a faulty gene copy from each parent. It is present from birth as a genetic condition rather than something acquired later. Genetic testing confirms the specific mutation.

Common features include an enlarged liver, low blood sugar episodes, poor growth in childhood, and muscle weakness that can worsen with age. Some people develop an enlarged, weakened heart muscle (cardiomyopathy). Liver-related symptoms often improve after puberty, while muscle symptoms can become more prominent in adulthood.

Yes, it requires lifelong monitoring because of the risk of low blood sugar, liver complications, and heart or muscle involvement, though severity varies between individuals. With appropriate dietary management and monitoring, many people live full and active lives. Regular cardiac and liver assessment is important to catch complications early.

Yes, it is an autosomal recessive genetic condition, meaning both parents must carry a faulty copy of the gene for a child to be affected. Each pregnancy between two carrier parents carries a one-in-four chance of an affected child. Carrier testing and genetic counselling are available for affected families.

Treatment centres on a high-protein diet and frequent feeding, sometimes including uncooked cornstarch, to maintain stable blood sugar and support muscle health. Regular monitoring of liver function, blood sugar, and heart function by a metabolic specialist guides ongoing management. Physiotherapy may help with muscle symptoms as they develop.

There is no cure, but dietary treatment can significantly reduce symptoms and slow complications, particularly liver-related problems, which often improve after childhood. Muscle and heart involvement tend to need ongoing management into adulthood. Research continues into more targeted treatments, but dietary therapy remains the mainstay.

GSD I causes more severe and frequent low blood sugar with no muscle involvement, while GSD III typically has somewhat milder blood sugar problems but adds muscle weakness and sometimes heart involvement, especially in the subtype affecting muscle. The enzyme defects are different, being glucose-6-phosphatase in GSD I and the debranching enzyme in GSD III. Both require specialist metabolic management, but the long-term complications differ.

Liver-related symptoms often improve significantly after puberty, but muscle and, in some subtypes, heart problems can progress in adulthood and need ongoing surveillance. Outlook is generally good with regular specialist follow-up and appropriate dietary management. Some adults require monitoring for heart failure related to cardiomyopathy.

Care is coordinated by a metabolic specialist from diagnosis, typically in early childhood, with scheduled reviews rather than only reactive visits. Any signs of low blood sugar, new muscle weakness, or breathlessness should prompt an earlier review. Cardiac assessment is usually built into the routine monitoring schedule given the risk of heart muscle involvement.